Overnight Health Care: Trump says he hopes Supreme Court strikes down ObamaCare | FDA approves remdesivir as COVID-19 treatment | Dems threaten to subpoena HHS over allegations of political interference at CDC
We'll be watching for plenty of back-and-forth on the coronavirus response at tonight's presidential debate, but first, President Trump gave Democrats some fodder for attacks with his comments on ObamaCare to "60 Minutes," and a new study points to thousands of avoidable COVID-19 deaths in the United States.
We'll start with the ObamaCare comments:
Trump says he hopes Supreme Court strikes down ObamaCare
President Trump says in a new interview with "60 Minutes" that he would like to see the Supreme Court "end" the Affordable Care Act (ACA) and that he would announce his own health care plan after the case is ruled on.
"It is developed. It is fully developed. It is going to be announced very soon when we see what happens with ObamaCare, which is not good," Trump said when questioned by CBS News correspondent Lesley Stahl on why he hasn't released the health care plan that he has long promised.
Trump would not elaborate on how the plan would protect those with preexisting conditions. He claimed that "pieces" of his plan had been released before, saying later that it "will" be developed and suggesting that despite his assurances it has not been fully formed.
I hope that they end it. It will be so good if they end it because we will come up with a plan," Trump said.
The lawsuit: Trump's own Justice Department signed on to the lawsuit seeking to strike the ACA, which was brought by a group of GOP state attorneys general, so it's not exactly a surprise that he wants the law gone. But the landmark health care reform law has proved popular with voters.
Contrast with Senate GOP: In Congress, on the other hand, Republicans are downplaying the chances of the ObamaCare lawsuit, which has become a political headache. "No one believes the Supreme Court is going to strike down the Affordable Care Act," Senate Majority Leader Mitch McConnell (R-Ky.) said last week during a debate with his Democratic challenger.
FDA grants full approval to remdesivir as COVID-19 treatment
The Food and ******* Administration (FDA) has granted full approval to the antiviral ******* remdesivir to treat COVID-19, manufacturer Gilead announced Thursday.
FDA initially granted emergency use authorization for remdesivir in May, which allowed doctors and hospitals to use the ******* to treat hospitalized patients without a full approval.
Remdesivir, which is administered in a hospital setting through an IV, showed modest results in reducing the hospitalizations of patients with severe cases of COVID-19.
It is now the only FDA-approved treatment for COVID-19.
The approval is based on three randomized controlled trials, including one sponsored by the National Institutes of Health.
In an open letter to the public, Gilead's chief medical officer Merdad Parsey acknowledged the results from a global World Health Organization trial, which found remsdesivir had no substantial impact on the survival of COVID-19 patients or the length of their hospital stays. But he took issue with the trial design and its implementation, and said the ones conducted in the U.S. result in high quality scientific evidence.
House Democrats threaten to subpoena HHS over allegations of political interference at CDC
House Majority Whip James Clyburn (D-S.C.), chairman of the Oversight and Reform Select subcommittee on the Coronavirus Crisis, threatened Thursday to issue subpoenas in the panel's investigation of alleged political interference by the Trump administration in Centers for Disease Control and Prevention (CDC) reports on the COVID-19 pandemic.
We'll be watching for plenty of back-and-forth on the coronavirus response at tonight's presidential debate, but first, President Trump gave Democrats some fodder for attacks with his comments on ObamaCare to "60 Minutes," and a new study points to thousands of avoidable COVID-19 deaths in the United States.
We'll start with the ObamaCare comments:
Trump says he hopes Supreme Court strikes down ObamaCare
President Trump says in a new interview with "60 Minutes" that he would like to see the Supreme Court "end" the Affordable Care Act (ACA) and that he would announce his own health care plan after the case is ruled on.
"It is developed. It is fully developed. It is going to be announced very soon when we see what happens with ObamaCare, which is not good," Trump said when questioned by CBS News correspondent Lesley Stahl on why he hasn't released the health care plan that he has long promised.
Trump would not elaborate on how the plan would protect those with preexisting conditions. He claimed that "pieces" of his plan had been released before, saying later that it "will" be developed and suggesting that despite his assurances it has not been fully formed.
I hope that they end it. It will be so good if they end it because we will come up with a plan," Trump said.
The lawsuit: Trump's own Justice Department signed on to the lawsuit seeking to strike the ACA, which was brought by a group of GOP state attorneys general, so it's not exactly a surprise that he wants the law gone. But the landmark health care reform law has proved popular with voters.
Contrast with Senate GOP: In Congress, on the other hand, Republicans are downplaying the chances of the ObamaCare lawsuit, which has become a political headache. "No one believes the Supreme Court is going to strike down the Affordable Care Act," Senate Majority Leader Mitch McConnell (R-Ky.) said last week during a debate with his Democratic challenger.
FDA grants full approval to remdesivir as COVID-19 treatment
The Food and ******* Administration (FDA) has granted full approval to the antiviral ******* remdesivir to treat COVID-19, manufacturer Gilead announced Thursday.
FDA initially granted emergency use authorization for remdesivir in May, which allowed doctors and hospitals to use the ******* to treat hospitalized patients without a full approval.
Remdesivir, which is administered in a hospital setting through an IV, showed modest results in reducing the hospitalizations of patients with severe cases of COVID-19.
It is now the only FDA-approved treatment for COVID-19.
The approval is based on three randomized controlled trials, including one sponsored by the National Institutes of Health.
In an open letter to the public, Gilead's chief medical officer Merdad Parsey acknowledged the results from a global World Health Organization trial, which found remsdesivir had no substantial impact on the survival of COVID-19 patients or the length of their hospital stays. But he took issue with the trial design and its implementation, and said the ones conducted in the U.S. result in high quality scientific evidence.
House Democrats threaten to subpoena HHS over allegations of political interference at CDC
House Majority Whip James Clyburn (D-S.C.), chairman of the Oversight and Reform Select subcommittee on the Coronavirus Crisis, threatened Thursday to issue subpoenas in the panel's investigation of alleged political interference by the Trump administration in Centers for Disease Control and Prevention (CDC) reports on the COVID-19 pandemic.
MSN
www.msn.com